Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aclaris Therapeutics, Inc. (ACRS) SEC filings page on Stock Titan provides access to the company’s public filings with the U.S. Securities and Exchange Commission, including current reports on Form 8-K and other key documents referenced in its investor communications. Aclaris is a Delaware-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company, and its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934.
For ACRS, SEC filings are an important source of information on financial results, clinical development progress, and corporate presentations. Recent Forms 8-K have furnished press releases announcing quarterly and year-to-date financial results, described as including revenue from contract research and licensing, research and development expenses tied to product candidates such as bosakitug, ATI-052 and ATI-2138, and general and administrative costs. Other 8-K filings have furnished R&D Day and corporate overview presentations and detailed top line results from the Phase 2a trial of ATI-2138 in atopic dermatitis.
Through this page, users can locate Aclaris’ current reports that summarize material events, such as updates to its clinical pipeline, conference calls discussing top line clinical data, and investor presentations. While the examples provided are 8-K filings, the SEC Filings page is also the natural place to look for Aclaris’ annual reports on Form 10-K, quarterly reports on Form 10-Q, and any proxy statements or registration statements the company files, which together outline its risk factors, business description, and governance structure.
Stock Titan enhances these filings with AI-powered tools that can help explain complex financial and scientific disclosures in plain language. For ACRS, this can be particularly useful when reviewing detailed discussions of its immuno-inflammatory pipeline, revenue components such as licensing and contract research, and non-cash items like royalty income and contingent consideration revaluations. The page also provides a path to monitor any future insider transaction reports on Form 4 or other ownership-related filings that may be associated with Aclaris’ executive officers and directors.
On 30 June 2025, Aclaris Therapeutics, Inc. (Nasdaq: ACRS) filed an 8-K solely to furnish an updated corporate overview presentation (Exhibit 99.1) under Item 7.01 – Regulation FD Disclosure. The deck has been posted to the company’s website and is not deemed “filed” for Exchange Act liability or for incorporation by reference. No financial results, strategic transactions, or operational updates were disclosed. All other sections, including Item 9.01, merely list the exhibit numbers, and the filing was signed by CFO Kevin Balthaser.